New trial aims to tailor breast cancer treatment using PET scans
NCT ID NCT06245889
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This pilot study tests whether adjusting chemotherapy based on early PET scan results can improve outcomes for people with stage 2 or 3 triple negative breast cancer. Participants receive four cycles of chemotherapy plus the immunotherapy drug pembrolizumab. A PET scan after the first cycle helps guide whether additional chemotherapy is needed before surgery. The study aims to see if early changes in PET signals predict whether the cancer is completely gone at surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (immunotherapy) combined with chemotherapy drugs (paclitaxel, carboplatin, doxorubicin, cyclophosphamide, olaparib, capecitabine)
What this could lead to
If successful, this could help personalize treatment for triple negative breast cancer, potentially reducing unnecessary chemotherapy and improving outcomes.
What could go wrong
This is a small pilot study with only 30 participants, so results may not apply broadly. The approach is complex and may not improve response rates over standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
RECRUITINGBaltimore, Maryland, 21287, United States
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
RECRUITINGBaltimore, Maryland, 21287, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••